AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $4,286,000 | $4,820,000 | $11,845,000 | $11,549,000 |
| Dep. & Amort. | $8,386,000 | $8,698,000 | $8,467,000 | $8,521,000 |
| Deferred Tax | -$1,449,000 | -$2,889,000 | -$1,931,000 | -$898,000 |
| Stock-Based Comp. | $911,000 | $747,000 | $671,000 | $692,000 |
| Change in WC | -$2,782,000 | $2,813,000 | -$258,000 | -$1,322,000 |
| Other Non-Cash | $9,454,000 | $8,650,000 | $6,149,000 | $4,235,000 |
| Operating Cash Flow | $18,806,000 | $22,839,000 | $24,943,000 | $22,777,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$974,000 | -$777,000 | -$695,000 | -$787,000 |
| Net Acquisitions | -$17,493,000 | -$1,223,000 | -$794,000 | -$1,902,000 |
| Inv. Purchases | -$73,000 | -$77,000 | -$1,438,000 | -$119,000 |
| Inv. Sales/Matur. | $555,000 | $55,000 | $1,530,000 | $98,000 |
| Other Inv. Act. | -$2,835,000 | $13,000 | $774,000 | $366,000 |
| Investing Cash Flow | -$20,820,000 | -$2,009,000 | -$623,000 | -$2,344,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $7,350,000 | -$4,149,000 | -$12,433,000 | -$8,414,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$1,708,000 | -$1,972,000 | -$1,487,000 | -$934,000 |
| Dividends Paid | -$11,025,000 | -$10,539,000 | -$10,043,000 | -$9,261,000 |
| Other Fin. Act. | $172,000 | -$562,000 | -$840,000 | -$430,000 |
| Financing Cash Flow | -$5,211,000 | -$17,222,000 | -$24,803,000 | -$19,039,000 |
| Forex Effect | -$65,000 | $5,000 | -$62,000 | -$97,000 |
| Net Chg. in Cash | -$7,290,000 | $3,613,000 | -$545,000 | $1,297,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $12,814,000 | $9,201,000 | $9,746,000 | $8,449,000 |
| End Cash | $5,524,000 | $12,814,000 | $9,201,000 | $9,746,000 |
| Free Cash Flow | $17,832,000 | $22,062,000 | $24,248,000 | $21,990,000 |